Condition: Diffuse Intrinsic Pontine Glioma · Diffuse Midline Glioma, H3 K27M-Mutant · Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
This is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB. rHSC-DIPGVax is an off-the-shelf neo-antigen heat shock protein containing 16 peptides reflecting neo-epitopes found in the majority of DIPG and DMG tumors. Newly diagnosed patients with DIPG and DMG who have completed radiation six to ten weeks prior to enrollment are eligible.
This description comes directly from the study's public registry record.
Monica Newmark, BS, RN · 312-227-4847 · MNewmark@luriechildrens.org
Ashley Plant-Fox, MD · 312-227-4858 · aplant@luriechildrens.org
Always discuss trial participation with your own doctor first.
| Children's Health Orange County (CHOC) | Orange, California, United States | Recruiting |
| Ann and Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| Dana-Farber Boston Children's Cancer and Blood Disorders Center | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04943848